Recent testosterone drop-off and risk of cardiovascular events

References

• Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22(5):414–433.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47–R71.
   PubMed Web of Science ®Google Scholar
• Bruck B, Brehme U, Gugel N, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. ATVB. 1997;17(10):2192–2199.
   Google Scholar
• Vikan T, Johnsen SH, Schirmer H, et al. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromsø study. Eur J Epidemiol. 2009;24(6):289–295.
   PubMed Web of Science ®Google Scholar
• Soisson V, Brailly-Tabard S, Empana JP, et al. Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men. Atherosclerosis. 2012;223(1):244–249.
   PubMed Web of Science ®Google Scholar
• Kwon H, Lee D-G, Kang HC, et al. The relationship between testosterone, metabolic syndrome, and mean carotid intima-media thickness in aging men. Aging Male. 2014;17(4):211–215.
   PubMed Web of Science ®Google Scholar
• Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–467.
   PubMed Web of Science ®Google Scholar
• Nezu T, Hosomi N, Aoki S, et al. Carotid intima-media thickness for atherosclerosis. J Atheroscler Thromb. 2016;23(1):18–31.
   PubMed Web of Science ®Google Scholar
• O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340(1):14–22.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94(7):2353–2359.
   PubMed Web of Science ®Google Scholar
• Son BK, Kojima T, Ogawa S, et al. Testosterone inhibits aneurysm formation and vascular inflammation in male mice. J Endocrinol. 2019;241(3):307–317.
   PubMed Web of Science ®Google Scholar
• Sarma AV, St. Sauver JL, Jacobson DJ, et al. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted county study and the flint men’s health study. Urology. 2014;83(1):88–93.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang X, Zhong Y, et al. Dynamic patterns of testosterone levels within Individuals and risk of prostate cancer among hypogonadal men: a longitudinal study. J Urol. 2018;199(2):465–473.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430–2439.
   PubMed Web of Science ®Google Scholar
• Sultan K, Haider A, Doros G, et al. Design and Conduct of a Real-World Single-Center Registry Study on Testosterone Therapy of Men with Hypogonadism. Androg Clin Res Ther. 2021;2(1):1–17.
   Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–480.
   PubMed Web of Science ®Google Scholar
• Huhtaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol. 2011;8(6):335–344.
   PubMed Web of Science ®Google Scholar
• Jiang M, Huhtaniemi I. Polymorphisms in androgen and estrogen receptor genes: effects on male aging. Exp Gerontol. 2004;39(11–12):1603–1611.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Carson C, Dobs A, et al. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67(5):545–557.
   PubMed Web of Science ®Google Scholar
• Srinath R, Gottesman RF, Hill Golden S, et al. Association between endogenous testosterone and cerebrovascular disease in the ARIC study (Atherosclerosis Risk in Communities). Stroke. 2016;47(11):2682–2688.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712–719.
   PubMed Web of Science ®Google Scholar
• Adorni MP, Zimetti F, Cangiano B, et al. High-density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism. J Clin Endocrinol Metab. 2019;104(8):3097–3107.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Ruscica M, Calabresi L, et al. HDL therapy today: from atherosclerosis, to stent compatibility to heart failure. Ann Med. 2019;51(7–8):345–359.
   PubMed Web of Science ®Google Scholar
• Alkamel A, Shafiee A, Jalali A, et al. The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med. 2014;17(8):545–550. doi:014178/AIM.005
   PubMed Web of Science ®Google Scholar
• Farias JM, Tinetti M, Khoury M, et al. Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(12):4698–4703.
   PubMed Web of Science ®Google Scholar
• Choi KM, Han K, Park S, et al. Implication of liver enzymes on incident cardiovascular diseases and mortality: a nationwide population-based cohort study. Sci Rep. 2018;8(1):3764.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211(1):182–186.
   PubMed Web of Science ®Google Scholar
• Gupta D, Lee Chuy K, Yang JC, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580–587.
   PubMed Web of Science ®Google Scholar
• Smith MR. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer. 2003;2(1):18–21.
   PubMedGoogle Scholar
• Tzortzis V, Samarinas M, Zachos I, et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens). 2017;16(2):115–123.
   PubMedGoogle Scholar
• Zareba P, Duivenvoorden W, Leong DP, et al. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–129.
   PubMed Web of Science ®Google Scholar
• Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456.
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396.
   PubMed Web of Science ®Google Scholar
• Collet T-H, Ewing SK, Ensrud KE. Endogenous testosterone levels and the risk of incident cardiovascular events in elderly men: the MrOS prospective study. J Endocr Soc. 2020;4(5):1–15.
   Web of Science ®Google Scholar
• Chmiel A, Mizia-Stec K, Wierzbicka-Chmiel J, et al. Low testosterone and sexual symptoms in men with acute coronary syndrome can be used to predict major adverse cardiovascular events during long-term follow-up. Andrology. 2015;3(6):1113–1118.
   PubMed Web of Science ®Google Scholar
• Srinath R, Golden SH, Carson KA, et al. Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities study. J Clin Endocrinol Metab. 2015;100(4):1602–1608.
   PubMed Web of Science ®Google Scholar
• Khasnavis S, Ghosh A, Roy A, et al. Castration induces parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem. 2013;288(29):20843–20855.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong Y, Taylor N, et al. Family history of prostate cancer and age-related trend of testosterone levels among US males: NHANES 2003–2004. Andrology. 2019;7(3):288–292.
   PubMed Web of Science ®Google Scholar